These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 27903809)
21. Screening for ovarian cancer in the general population. Gentry-Maharaj A; Menon U Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):243-56. PubMed ID: 22182415 [TBL] [Abstract][Full Text] [Related]
22. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Nyante SJ; Black A; Kreimer AR; Duggan MA; Carreon JD; Kessel B; Buys SS; Ragard LR; Johnson KA; Dunn BK; Lamerato L; Commins JM; Berg CD; Sherman ME Gynecol Oncol; 2011 Mar; 120(3):474-9. PubMed ID: 21144559 [TBL] [Abstract][Full Text] [Related]
23. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T Int J Gynecol Cancer; 2008; 18(3):414-20. PubMed ID: 17645503 [TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Berek JS; Bast RC Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006 [TBL] [Abstract][Full Text] [Related]
25. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255 [TBL] [Abstract][Full Text] [Related]
26. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital]. Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203 [TBL] [Abstract][Full Text] [Related]
27. Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center. Gren LH; Lamerato LE; Wright P; Marcus PM Rev Recent Clin Trials; 2015; 10(3):194-9. PubMed ID: 26238206 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer. Torky HA; Sherif A; Abo-Louz A; Ali M; Ahmed A; Ali A Gynecol Obstet Invest; 2018; 83(5):461-465. PubMed ID: 29131023 [TBL] [Abstract][Full Text] [Related]
30. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Andersen MR; Goff BA; Lowe KA; Scholler N; Bergan L; Dresher CW; Paley P; Urban N Cancer; 2008 Aug; 113(3):484-9. PubMed ID: 18615684 [TBL] [Abstract][Full Text] [Related]
31. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. Sankaranarayanan R; Ramadas K; Thara S; Muwonge R; Prabhakar J; Augustine P; Venugopal M; Anju G; Mathew BS J Natl Cancer Inst; 2011 Oct; 103(19):1476-80. PubMed ID: 21862730 [TBL] [Abstract][Full Text] [Related]
32. CA 125 as a screening test for ovarian cancer. Hakama M; Stenman UH; Knekt P; Järvisalo J; Hakulinen T; Maatela J; Aromaa A J Med Screen; 1996; 3(1):40-2. PubMed ID: 8861050 [TBL] [Abstract][Full Text] [Related]
33. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women. Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468 [TBL] [Abstract][Full Text] [Related]
34. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. van Nagell JR; DePriest PD; Ueland FR; DeSimone CP; Cooper AL; McDonald JM; Pavlik EJ; Kryscio RJ Cancer; 2007 May; 109(9):1887-96. PubMed ID: 17373668 [TBL] [Abstract][Full Text] [Related]
35. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134 [TBL] [Abstract][Full Text] [Related]
36. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. Prayer L; Kainz C; Kramer J; Stiglbauer R; Schurawitzki H; Baldt M; Schima W; Poelzleitner D; Reinthaller A; Koelbl H J Comput Assist Tomogr; 1993; 17(4):626-32. PubMed ID: 8331235 [TBL] [Abstract][Full Text] [Related]
37. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S; Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524 [TBL] [Abstract][Full Text] [Related]
38. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Jacobs I; Davies AP; Bridges J; Stabile I; Fay T; Lower A; Grudzinskas JG; Oram D BMJ; 1993 Apr; 306(6884):1030-4. PubMed ID: 8490497 [TBL] [Abstract][Full Text] [Related]